Physician profile
James Turro
NPI 1497700561
$2,691.63
in general payments reported to CMS, 2019-2025
20 companies · $544 in 2025
The $544 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $242 · 2021: $158 · 2022: $171 · 2023: $419 · 2024: $756 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,719.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $607.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $540.57 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $380.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $261.35 | 2019-2025 | |
| Hologic Sales and Service, LLC | $139.07 | 2024 | Acessa Provu System |
| Exact Sciences Corporation | $116.82 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $99.82 | 2019-2021 | |
| Bausch Health US, LLC | $88.98 | 2021-2023 | Aplenzin |
| Dexcom, INC. | $87.23 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $62.88 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.19 | 2020-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $41.68 | 2022 | |
| Novartis Pharmaceuticals Corporation | $38.20 | 2021-2023 | |
| Abbott Laboratories | $37.96 | 2021-2023 | Freestyle Libre 3 |
| Abbvie INC. | $29.73 | 2020-2023 | Ubrelvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $27.22 | 2023 | Afrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $25.22 | 2019-2020 | |
| Glaxosmithkline, LLC. | $16.11 | 2022 | |
| Medtronic, INC. | $15.71 | 2023 | Closurefast |
| Merck Sharp & Dohme LLC | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Turro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.